Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.
Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6:20, 171 64, Solna, Stockholm, Sweden.
Endocr Pathol. 2020 Jun;31(2):156-165. doi: 10.1007/s12022-020-09616-3.
Parathyroid lipoadenomas (PLAs) are rare tumors, and case descriptions are limited, < 80 to date. As a consequence, scarce information regarding the etiology of these enigmatic lesions is available. We searched our departmental pathology database for PLAs diagnosed between 1992 and 2020, reexamined the histology of each case, and recorded clinical parameters from the patients' medical charts. As the diagnostic criteria of this lesion vary over this time period, we defined PLA as an enlarged parathyroid gland with > 50% fat on histologic examination with preoperative evidence of primary hyperparathyroidism (PHPT). A total of 8 bona fide PLA cases and 2 equivocal PLAs (close to 50% fat) were included. As approximately 4000 conventional parathyroid adenomas were diagnosed at our department during the same time interval, the prevalence of PLA was 0.20%. PLA patients were predominately female (63%) and presented with classical PHPT-related symptoms. Majority of cases were successfully located preoperatively and had an average tumor weight of 445 mg. Histologically, all PLAs consisted of > 50% mature adipose tissue, except a single case with brown fat. Of note, PLA patients exhibited a body mass index in line with PHPT patients in general, but a relatively high, near-significant prevalence of arterial hypertension was observed when compared to tumors with less fat (P = 0.0584). Future studies on this finding might be warranted. To summarize, we present one of the largest institutional PLA case series to date, and conclude that PLAs are rare, sporadic tumors mirroring many clinical aspects of conventional adenomas-with a potential coupling to hypertension worthy of follow-up studies.
甲状旁腺脂肪腺瘤 (PLA) 是一种罕见的肿瘤,目前仅有 <80 例的病例描述,因此,对于这些神秘病变的病因知之甚少。我们在我院病理数据库中检索了 1992 年至 2020 年期间诊断的 PLA,并重新检查了每个病例的组织学,并从患者的病历中记录了临床参数。由于在此期间该病变的诊断标准有所不同,我们将 PLA 定义为组织学上有 >50%脂肪的增大甲状旁腺腺体,且术前有原发性甲状旁腺功能亢进 (PHPT) 的证据。共纳入 8 例明确的 PLA 病例和 2 例可疑的 PLA(接近 50%脂肪)。由于在此期间我院共诊断了大约 4000 例常规甲状旁腺腺瘤,因此 PLA 的患病率为 0.20%。PLA 患者主要为女性(63%),表现为典型的 PHPT 相关症状。大多数病例在术前成功定位,肿瘤平均重量为 445mg。组织学上,所有 PLA 均由 >50%成熟脂肪组织组成,除了一个单独的病例有棕色脂肪。值得注意的是,与脂肪含量较低的肿瘤相比,PLA 患者的体重指数与 PHPT 患者相当,但高血压的患病率相对较高,接近显著(P=0.0584)。可能需要对这一发现进行进一步的研究。综上所述,我们报告了迄今为止最大的 PLA 系列病例之一,并得出结论,PLA 是罕见的、散发性肿瘤,与常规腺瘤的许多临床方面相似,与高血压有潜在关联,值得进一步研究。